Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Döring G[au]:

Cystic fibrosis. Ratjen F et al. Lancet. (2003)

Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Figueiredo N et al. Immunity. (2013)

Treatment of lung infection in patients with cystic fibrosis: current and future strategies. Döring G et al. J Cyst Fibros. (2012)

Search results

Items: 1 to 50 of 352

1.

Oxygen-dependent regulation of c-di-GMP synthesis by SadC controls alginate production in Pseudomonas aeruginosa.

Schmidt A, Hammerbacher AS, Bastian M, Nieken KJ, Klockgether J, Merighi M, Lapouge K, Poschgan C, Kölle J, Acharya KR, Ulrich M, Tümmler B, Unden G, Kaever V, Lory S, Haas D, Schwarz S, Döring G.

Environ Microbiol. 2016 Oct;18(10):3390-3402. doi: 10.1111/1462-2920.13208. Epub 2016 Feb 4.

PMID:
26743546
2.

Genetic Deletion and Pharmacological Inhibition of PI3K γ Reduces Neutrophilic Airway Inflammation and Lung Damage in Mice with Cystic Fibrosis-Like Lung Disease.

Galluzzo M, Ciraolo E, Lucattelli M, Hoxha E, Ulrich M, Campa CC, Lungarella G, Doring G, Zhou-Suckow Z, Mall M, Hirsch E, De Rose V.

Mediators Inflamm. 2015;2015:545417. doi: 10.1155/2015/545417. Epub 2015 Jun 21.

3.

Integrated whole-genome screening for Pseudomonas aeruginosa virulence genes using multiple disease models reveals that pathogenicity is host specific.

Dubern JF, Cigana C, De Simone M, Lazenby J, Juhas M, Schwager S, Bianconi I, Döring G, Eberl L, Williams P, Bragonzi A, Cámara M.

Environ Microbiol. 2015 Nov;17(11):4379-93. doi: 10.1111/1462-2920.12863. Epub 2015 May 14.

4.

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in children with cystic fibrosis.

Daines C, VanDeVanter D, Khan U, Emerson J, Heltshe S, McNamara S, Anstead M, Langkamp M, Doring G, Ratjen F, Ramsey B, Gibson RL, Morgan W, Rosenfeld M; EPIC Investigators.

J Cyst Fibros. 2014 Sep;13(5):542-9. doi: 10.1016/j.jcf.2014.06.005. Epub 2014 Jul 11.

5.

Invariant natural killer T (iNKT) cells prevent autoimmunity, but induce pulmonary inflammation in cystic fibrosis.

Siegmann N, Worbs D, Effinger F, Bormann T, Gebhardt M, Ulrich M, Wermeling F, Müller-Hermelink E, Biedermann T, Tighe M, Edwards MJ, Caldwell C, Leadbetter E, Karlsson MC, Becker KA, Gulbins E, Döring G.

Cell Physiol Biochem. 2014;34(1):56-70. doi: 10.1159/000362984. Epub 2014 Jun 16.

6.

Neutrophil elastase-mediated increase in airway temperature during inflammation.

Schmidt A, Belaaouaj A, Bissinger R, Koller G, Malleret L, D'Orazio C, Facchinelli M, Schulte-Hubbert B, Molinaro A, Holst O, Hammermann J, Schniederjans M, Meyer KC, Damkiaer S, Piacentini G, Assael B, Bruce K, Häußler S, LiPuma JJ, Seelig J, Worlitzsch D, Döring G.

J Cyst Fibros. 2014 Dec;13(6):623-31. doi: 10.1016/j.jcf.2014.03.004. Epub 2014 Apr 6.

7.

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.

Konstan MW, Döring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton A; Investigators and Coordinators of BI Trial 543.45.

J Cyst Fibros. 2014 Mar;13(2):148-55. doi: 10.1016/j.jcf.2013.12.009. Epub 2014 Jan 17.

8.

Anthracyclines induce DNA damage response-mediated protection against severe sepsis.

Figueiredo N, Chora A, Raquel H, Pejanovic N, Pereira P, Hartleben B, Neves-Costa A, Moita C, Pedroso D, Pinto A, Marques S, Faridi H, Costa P, Gozzelino R, Zhao JL, Soares MP, Gama-Carvalho M, Martinez J, Zhang Q, Döring G, Grompe M, Simas JP, Huber TB, Baltimore D, Gupta V, Green DR, Ferreira JA, Moita LF.

Immunity. 2013 Nov 14;39(5):874-84. doi: 10.1016/j.immuni.2013.08.039. Epub 2013 Oct 31.

9.

BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs.

Döring G, Bragonzi A, Paroni M, Aktürk FF, Cigana C, Schmidt A, Gilpin D, Heyder S, Born T, Smaczny C, Kohlhäufl M, Wagner TO, Loebinger MR, Bilton D, Tunney MM, Elborn JS, Pier GB, Konstan MW, Ulrich M.

J Cyst Fibros. 2014 Mar;13(2):156-63. doi: 10.1016/j.jcf.2013.10.007. Epub 2013 Oct 31.

10.

Evaluation of specific immune response in early P. aeruginosa infection in cystic fibrosis patients.

Dolce D, Cariani L, Campana S, Ravenni N, Mergni G, Biffi A, Colombo C, Gagliardini R, Cirilli N, Manso E, Padoan R, Soncini E, Forte FR, D'Aprile A, Ratclif L, Amboni M, Casciaro R, Minicucci L, Borio T, Cosimi A, Vieni G, Zinnarello C, Fiscarelli E, Collura M, Pensabene T, Braggion C, Döring G, Taccetti G.

J Cyst Fibros. 2014 Jan;13(1):116-7. doi: 10.1016/j.jcf.2013.08.003. Epub 2013 Sep 7. No abstract available.

11.

Lactate levels in airways of patients with cystic fibrosis and idiopathic pulmonary fibrosis.

Worlitzsch D, Meyer KC, Döring G.

Am J Respir Crit Care Med. 2013 Jul 1;188(1):111. doi: 10.1164/rccm.201211-2042LE. No abstract available.

PMID:
23815725
12.

Therapy of CF-patients with amitriptyline and placebo--a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study.

Nährlich L, Mainz JG, Adams C, Engel C, Herrmann G, Icheva V, Lauer J, Deppisch C, Wirth A, Unger K, Graepler-Mainka U, Hector A, Heyder S, Stern M, Döring G, Gulbins E, Riethmüller J.

Cell Physiol Biochem. 2013;31(4-5):505-12. doi: 10.1159/000350071. Epub 2013 Apr 2.

13.

Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia.

Miller CC, Hergott CA, Rohan M, Arsenault-Mehta K, Döring G, Mehta S.

J Cyst Fibros. 2013 Dec;12(6):817-20. doi: 10.1016/j.jcf.2013.01.008. Epub 2013 Mar 6.

14.

A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection.

Tiringer K, Treis A, Fucik P, Gona M, Gruber S, Renner S, Dehlink E, Nachbaur E, Horak F, Jaksch P, Döring G, Crameri R, Jung A, Rochat MK, Hörmann M, Spittler A, Klepetko W, Akdis CA, Szépfalusi Z, Frischer T, Eiwegger T.

Am J Respir Crit Care Med. 2013 Mar 15;187(6):621-9. doi: 10.1164/rccm.201206-1150OC. Epub 2013 Jan 10.

PMID:
23306544
15.

Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease.

Rieber N, Brand A, Hector A, Graepler-Mainka U, Ost M, Schäfer I, Wecker I, Neri D, Wirth A, Mays L, Zundel S, Fuchs J, Handgretinger R, Stern M, Hogardt M, Döring G, Riethmüller J, Kormann M, Hartl D.

J Immunol. 2013 Feb 1;190(3):1276-84. doi: 10.4049/jimmunol.1202144. Epub 2012 Dec 31.

16.

Treatment of lung infection in patients with cystic fibrosis: current and future strategies.

Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group.

J Cyst Fibros. 2012 Dec;11(6):461-79. doi: 10.1016/j.jcf.2012.10.004. Epub 2012 Nov 6. Review.

17.

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study.

Schuster A, Haliburn C, Döring G, Goldman MH; Freedom Study Group.

Thorax. 2013 Apr;68(4):344-50. doi: 10.1136/thoraxjnl-2012-202059. Epub 2012 Nov 7.

18.

The novel cis-encoded small RNA h2cR is a negative regulator of hfq2 in Burkholderia cenocepacia.

Ramos CG, da Costa PJ, Döring G, Leitão JH.

PLoS One. 2012;7(10):e47896. doi: 10.1371/journal.pone.0047896. Epub 2012 Oct 17.

19.

Expression and regulation of interferon-related development regulator-1 in cystic fibrosis neutrophils.

Hector A, Kormann M, Kammermeier J, Burdi S, Marcos V, Rieber N, Mays L, Illig T, Klopp N, Falkenstein F, Kappler M, Riethmueller J, Graepler-Mainka U, Stern M, Eickmeier O, Serve F, Zielen S, Döring G, Griese M, Hartl D.

Am J Respir Cell Mol Biol. 2013 Jan;48(1):71-7. doi: 10.1165/rcmb.2012-0061OC. Epub 2012 Oct 4.

PMID:
23043087
20.

Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B.

J Cyst Fibros. 2013 Mar;12(2):147-53. doi: 10.1016/j.jcf.2012.08.001. Epub 2012 Sep 1.

21.

Innate immunity in cystic fibrosis lung disease.

Hartl D, Gaggar A, Bruscia E, Hector A, Marcos V, Jung A, Greene C, McElvaney G, Mall M, Döring G.

J Cyst Fibros. 2012 Sep;11(5):363-82. doi: 10.1016/j.jcf.2012.07.003. Epub 2012 Aug 20. Review.

22.

When is mass spectrometry combined with affinity approaches essential? A case study of tyrosine nitration in proteins.

Petre BA, Ulrich M, Stumbaum M, Bernevic B, Moise A, Döring G, Przybylski M.

J Am Soc Mass Spectrom. 2012 Nov;23(11):1831-40. doi: 10.1007/s13361-012-0461-4. Epub 2012 Aug 21.

PMID:
22907170
23.

Vaccine development for patients with cystic fibrosis.

Döring G.

Expert Rev Vaccines. 2012 Mar;11(3):259-61. doi: 10.1586/erv.12.1. No abstract available.

PMID:
22380816
24.

MudPIT analysis of released proteins in Pseudomonas aeruginosa laboratory and clinical strains in relation to pro-inflammatory effects.

Bergamini G, Di Silvestre D, Mauri P, Cigana C, Bragonzi A, De Palma A, Benazzi L, Döring G, Assael BM, Melotti P, Sorio C.

Integr Biol (Camb). 2012 Mar;4(3):270-9. doi: 10.1039/c2ib00127f. Epub 2012 Feb 1.

PMID:
22298109
25.
26.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis.

Rogers GB, Hoffman LR, Döring G.

J Cyst Fibros. 2011 Dec;10(6):387-400. doi: 10.1016/j.jcf.2011.06.014. Epub 2011 Jul 19. Review.

27.

Molecular epidemiology of meticillin-resistant Staphylococcus aureus in Italian cystic fibrosis patients: a national overview.

Cocchi P, Cariani L, Favari F, Lambiase A, Fiscarelli E, Gioffré FV, d'Aprile A, Manso E, Taccetti G, Braggion C, Döring G, de Martino M, Campana S.

J Cyst Fibros. 2011 Dec;10(6):407-11. doi: 10.1016/j.jcf.2011.06.005. Epub 2011 Jul 12.

28.

Lactate in cystic fibrosis sputum.

Bensel T, Stotz M, Borneff-Lipp M, Wollschläger B, Wienke A, Taccetti G, Campana S, Meyer KC, Jensen PØ, Lechner U, Ulrich M, Döring G, Worlitzsch D.

J Cyst Fibros. 2011 Jan;10(1):37-44. doi: 10.1016/j.jcf.2010.09.004. Epub 2010 Oct 13.

29.

Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.

Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, Ulrich M, Molin S, Riethmüller J, Döring G.

J Infect Dis. 2010 Nov 15;202(10):1585-92. doi: 10.1086/656788. Epub 2010 Oct 13.

PMID:
20942647
30.

Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients.

Döring G.

Int J Med Microbiol. 2010 Dec;300(8):573-7. doi: 10.1016/j.ijmm.2010.08.010. Review.

PMID:
20940108
31.

Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis.

Ulrich M, Beer I, Braitmaier P, Dierkes M, Kummer F, Krismer B, Schumacher U, Gräpler-Mainka U, Riethmüller J, Jensen PØ, Bjarnsholt T, Høiby N, Bellon G, Döring G.

Thorax. 2010 Nov;65(11):978-84. doi: 10.1136/thx.2010.137745. Epub 2010 Sep 29.

PMID:
20880875
32.

CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation.

Marcos V, Zhou Z, Yildirim AO, Bohla A, Hector A, Vitkov L, Wiedenbauer EM, Krautgartner WD, Stoiber W, Belohradsky BH, Rieber N, Kormann M, Koller B, Roscher A, Roos D, Griese M, Eickelberg O, Döring G, Mall MA, Hartl D.

Nat Med. 2010 Sep;16(9):1018-23. doi: 10.1038/nm.2209. Epub 2010 Sep 5. Retraction in: Nat Med. 2011 Jul;17(7):899.

PMID:
20818377
33.

Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone.

Alten R, Döring G, Cutolo M, Gromnica-Ihle E, Witte S, Straub R, Buttgereit F.

J Rheumatol. 2010 Oct;37(10):2025-31. doi: 10.3899/jrheum.100051. Epub 2010 Aug 3.

34.

Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease.

Döring G, Parameswaran IG, Murphy TF.

FEMS Microbiol Rev. 2011 Jan;35(1):124-46. doi: 10.1111/j.1574-6976.2010.00237.x. Review.

35.

Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host.

Gronbach K, Eberle U, Müller M, Olschläger TA, Dobrindt U, Leithäuser F, Niess JH, Döring G, Reimann J, Autenrieth IB, Frick JS.

Infect Immun. 2010 Jul;78(7):3036-46. doi: 10.1128/IAI.00218-10. Epub 2010 Apr 26.

36.

Alterations in ceramide concentration and pH determine the release of reactive oxygen species by Cftr-deficient macrophages on infection.

Zhang Y, Li X, Grassmé H, Döring G, Gulbins E.

J Immunol. 2010 May 1;184(9):5104-11. doi: 10.4049/jimmunol.0902851. Epub 2010 Mar 29.

37.

Alveolar inflammation in cystic fibrosis.

Ulrich M, Worlitzsch D, Viglio S, Siegmann N, Iadarola P, Shute JK, Geiser M, Pier GB, Friedel G, Barr ML, Schuster A, Meyer KC, Ratjen F, Bjarnsholt T, Gulbins E, Döring G.

J Cyst Fibros. 2010 May;9(3):217-27. doi: 10.1016/j.jcf.2010.03.001. Epub 2010 Mar 29.

38.

Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.

Campodónico VL, Llosa NJ, Grout M, Döring G, Maira-Litrán T, Pier GB.

Infect Immun. 2010 Feb;78(2):746-55. doi: 10.1128/IAI.00806-09. Epub 2009 Dec 7.

39.

Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis.

Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, van Gennip M, Ciofu O, Mandsberg L, Kharazmi A, Döring G, Givskov M, Høiby N, Jensen PØ.

Thorax. 2010 Jan;65(1):57-62. doi: 10.1136/thx.2009.114512. Epub 2009 Oct 21.

PMID:
19846469
40.

Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.

Becker KA, Riethmüller J, Lüth A, Döring G, Kleuser B, Gulbins E.

Am J Respir Cell Mol Biol. 2010 Jun;42(6):716-24. doi: 10.1165/rcmb.2009-0174OC. Epub 2009 Jul 27.

PMID:
19635928
41.

Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis.

Riethmüller J, Anthonysamy J, Serra E, Schwab M, Döring G, Gulbins E.

Cell Physiol Biochem. 2009;24(1-2):65-72. doi: 10.1159/000227814. Epub 2009 Jul 1.

42.

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.

Heijerman H, Westerman E, Conway S, Touw D, Döring G; consensus working group.

J Cyst Fibros. 2009 Sep;8(5):295-315. doi: 10.1016/j.jcf.2009.04.005. Epub 2009 Jun 25. Review.

43.

Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence.

Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari S, Rejman J, Di Serio C, Döring G, Tümmler B.

Am J Respir Crit Care Med. 2009 Jul 15;180(2):138-45. doi: 10.1164/rccm.200812-1943OC. Epub 2009 May 7.

PMID:
19423715
44.

Resistance to dermcidin-derived peptides is independent of bacterial protease activity.

Senyürek I, Döring G, Kalbacher H, Deeg M, Peschel A, Wolz C, Schittek B.

Int J Antimicrob Agents. 2009 Jul;34(1):86-90. doi: 10.1016/j.ijantimicag.2008.12.008. Epub 2009 Feb 7.

PMID:
19201578
45.

Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.

Worlitzsch D, Rintelen C, Böhm K, Wollschläger B, Merkel N, Borneff-Lipp M, Döring G.

Clin Microbiol Infect. 2009 May;15(5):454-60. doi: 10.1111/j.1469-0691.2008.02659.x. Epub 2009 Jan 22.

46.

Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease.

Döring G, Gulbins E.

Cell Microbiol. 2009 Feb;11(2):208-16. doi: 10.1111/j.1462-5822.2008.01271.x. Epub 2008 Dec 2. Review.

PMID:
19068098
47.

Temocillin in cystic fibrosis: a retrospective pilot study.

Kent L, Bradley JM, France M, Döring G, Carryn S, Bradbury I, Rendall J, Jones A, Elborn JS.

J Cyst Fibros. 2008 Nov;7(6):551-4. doi: 10.1016/j.jcf.2008.06.005. Epub 2008 Aug 15.

48.

Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.

Steinkamp G, Schmitt-Grohe S, Döring G, Staab D, Pfründer D, Beck G, Schubert R, Zielen S.

Respir Med. 2008 Nov;102(11):1643-53. doi: 10.1016/j.rmed.2008.03.009. Epub 2008 Aug 12.

49.

Post-translational tyrosine nitration of eosinophil granule toxins mediated by eosinophil peroxidase.

Ulrich M, Petre A, Youhnovski N, Prömm F, Schirle M, Schumm M, Pero RS, Doyle A, Checkel J, Kita H, Thiyagarajan N, Acharya KR, Schmid-Grendelmeier P, Simon HU, Schwarz H, Tsutsui M, Shimokawa H, Bellon G, Lee JJ, Przybylski M, Döring G.

J Biol Chem. 2008 Oct 17;283(42):28629-40. doi: 10.1074/jbc.M801196200. Epub 2008 Aug 11.

50.

Validation criteria for nucleic acid amplification techniques for bacterial infections.

Döring G, Unertl K, Heininger A.

Clin Chem Lab Med. 2008;46(7):909-18. doi: 10.1515/CCLM.2008.152. Review.

PMID:
18605949

Supplemental Content

Loading ...
Support Center